Trial · NCT07363941
HEIGHT-BASED AND CONVENTIONAL SPINAL ANAESTHETIC DOSING IN GERIATRIC PATIENTS
NCT07363941, Not applicable, Recruiting, Shaheed Mohtarma Benazir Bhutto Institue of Trauma
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. HEIGHT-BASED AND CONVENTIONAL SPINAL ANAESTHETIC DOSING IN GERIATRIC PATIENTS. Trials, record NCT07363941. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07363941
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- HEIGHT-BASED AND CONVENTIONAL SPINAL ANAESTHETIC DOSING IN GERIATRIC PATIENTS
- NCT number
- NCT07363941
- Status
- Recruiting
- Phases
- Not applicable
- Enrollment
- 104 participants, estimated
- Lead sponsor
- Shaheed Mohtarma Benazir Bhutto Institue of Trauma
- Conditions
- Geriatric Population, Spinal Anesthesia Induced Hypotension, Spinal Anesthesia in Elderly Patients
- Interventions
- Group A : Spinal Anaesthetic Dose, Group B : Conventional Dose
- First posted
- 2026-01-23
- Last updated
- 2026-01-23
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | HYPOTENSION | Subsequent to the administration of spinal anaesthesia till the end of sensory and motor blockade | Defined as a decrease of ≥20% in mean arterial pressure (MAP) from baseline or an absolute MAP \<65 mmHg at any point during surgery, recorded using non-invasive blood pressure monitoring at five-minute intervals |
| Primary | BRADYCARDIA | Subsequent to the administration of spinal anaesthesia till the end of sensory and motor blockade | It will be defined in terms of a heart rate of ≤ 60 beats/minute during surgery |
| Primary | ONSET OF SENSORY BLOCK | Subsequent to the administration of spinal anaesthesia till the attainment of sensory blockade | It will be defined as the time interval (in minutes) from the completion of intrathecal injection of bupivacaine to the loss of pinprick sensation at the T10 dermatome. The assessment will be carried out using a sterile blunt 23-gauge needle at one-minute intervals until loss of sensation is confirmed. |
| Primary | DURATION OF SENSORY BLOCK | Subsequent to the administration of spinal anaesthesia till the end of sensory blockade | It will be defined as the time interval (in minutes) from the onset of sensory block at the T10 dermatome (confirmed by loss of pinprick sensation) to the reappearance of sensation at the same dermatome level. The response will be assessed every 5 minutes using a sterile blunt 23-gauge needle. |
| Primary | ONSET OF MOTOR BLOCK | Subsequent to the administration of spinal anaesthesia till the attainment of motor blockade | It will be defined as the time duration (in minutes) between the completion of intrathecal administration of bupivacaine until the patient develops Bromage III |
| Primary | DURATION OF MOTOR BLOCK | Subsequent to the administration of spinal anaesthesia till the end of motor blockade | The duration of motor block is defined as the time duration (in minutes) from the onset of motor block (inability to move feet) until the patient regains the ability to voluntarily move both feet. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers6
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07363941
GET https://conductscience.org/api/trials/v1/NCT07363941/registered